Look for:

Our offer for

VERTEX PHARMACEUTICAL


ISIN:
US92532F1003
WKN:
92532F100

2021/01/22 22:00:00
Price
237.59 USD
Difference -0.44% (-1.05)

General attributes

ISINUS92532F1003
SymbolVRTX
ExchangeNasdaq
CurrencyUSD
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)50,770 EUR
BenchmarkS&P 500

Market data

Bid (Bid size)238.45 USD (100)
Ask (Ask size)240.93 USD (100)
Open237.25 USD
High241.83 USD
Low236.99 USD
Close (prev. day)238.64 USD
VWAP238.852223 USD
Volume (pcs)1,258,224
Trading volume300,626,371.01
Number of trades23,364
Last size161,275

Futures and Options

Related Futures-
Related Options-

PDF Downloads

Annual report: VERTEX PHARMACEUTICALPDF Download

Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research



2021/01/22 22:00:00
Price
237.59 USD
Difference -0.44% (-1.05)

General attributes

ISINUS92532F1003
SymbolVRTX
ExchangeNasdaq
CurrencyUSD
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)50,770 EUR
BenchmarkS&P 500

Market data

Bid (Bid size)238.45 USD (100)
Ask (Ask size)240.93 USD (100)
Open237.25 USD
High241.83 USD
Low236.99 USD
Close (prev. day)238.64 USD
VWAP238.852223 USD
Volume (pcs)1,258,224
Trading volume300,626,371.01
Number of trades23,364
Last size161,275

Performance and Risk

6M1Y3Y
Perf (%)-18.42%+1.27%+46.74%
Perf (abs.)-53.64+2.98+75.68
Beta0.970.820.92
Volatility43.1347.6237.16
Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

Ø price 5 days | Ø volume 5 days (pcs.)234.08 USD (1,754,347)
Ø price 30 days | Ø volume 30 days (pcs.)231.74 USD (1,598,437)
Ø price 100 days | Ø volume 100 days (pcs.)238.05 USD (1,889,830)
Ø price 250 days | Ø volume 250 days (pcs.)251.96 USD (1,863,556)
YTD High | date241.83 USD (2021/01/22)
YTD Low | date222.31 USD (2021/01/06)
52 Weeks High | date306.08 USD (2020/07/07)
52 Weeks Low | date197.47 USD (2020/03/18)

All listings for VERTEX PHARMACEUTICAL

Exchange  DateTimePriceTrading volume (mio.)Number of trades
Xetra2021/01/2217:35196.24 EUR0.027
Vienna Stock Exchange2021/01/2217:32196.50 EUR0.0511
Tradegate2021/01/2222:26195.26 EUR0.1741
Stuttgart2021/01/2217:59196.30 EUR0.0010
Nasdaq2021/01/2222:00237.59 USD300.6323,364
Munich2021/01/2208:01194.48 EUR0.002
London Stock Exchange2021/01/2216:16240.4382 USD0.056
Hanover2021/01/2208:02194.44 EUR0.002
Hamburg2021/01/2208:02194.44 EUR0.002
Frankfurt2021/01/2218:27196.80 EUR0.001
Duesseldorf2021/01/2219:31197.08 EUR0.0023
Berlin2021/01/2208:08194.40 EUR0.002

Company Logo

https://gateway.mdgms.com/extern/logo_image.html?ID_LOGO=15368&ID_TYPE_IMAGE_LOGO=2

Contact Details

VERTEX PHARMACEUTICALS INC.
Michael Partridge
Northern Avenue 50 02210 Boston, Massachusetts
Telefon: +1-617-341-6100
Fax: -
E-mail: investorinfo@vrtx.com

PDF Downloads

Annual report: VERTEX PHARMACEUTICALPDF Download

Company Profile

Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative medicines so people with serious diseases can lead better lives. In addition to its clinical development programs focused on cystic fibrosis, Vertex has more than a dozen ongoing research programs aimed at other serious and life-threatening diseases. Founded in 1989 in Cambridge, Mass., Vertex today has research and development sites and commercial offices in the United States, Europe, Canada and Australia. For five years in a row, Science magazine has named Vertex one of its Top Employers in the life sciences.

Members of Management Board

Jeffrey LeidenChairman of Board of Directors
Yuchun LeeMember of Board of Directors
Terrence C. KearneyMember of Board of Directors
Reshma KewalramaniMember of Board of Directors
Margaret McGlynnMember of Board of Directors
Lloyd CarneyMember of Board of Directors
Diana McKenzieMember of Board of Directors
Bruce I. SachsMember of Board of Directors
Sangeeta N. BhatiaMember of Board of Directors
Alan GarberMember of Board of Directors
Reshma Kewalramani, M.D.Chairman of Managing Board
Stuart A. ArbuckleMember of Executive Committee
Stephanie FranklinMember of Executive Committee
Paul NegulescuMember of Executive Committee
Nina DevlinMember of Executive Committee
Nia Tatsis, Ph.D.Member of Executive Committee
Mike TirozziMember of Executive Committee
Michael J. PariniMember of Executive Committee
Michael PartridgeMember of Executive Committee
Mark BunnageMember of Executive Committee






Accept

We use cookies and web analysis software to give you the best possible experience on our website. By continuing to browse this website, you consent for these tools to be used. For more details and how to opt out of these, please read our Data protection policy.

INFORMATION FOR PRIVATE CLIENTS / CONSUMERS

Any information, material and services regarding financial instruments and securities provided by Erste Group Bank AG or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites”) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions (the “Interested Party“).

The publication and distribution of information as well as offering and selling of products and services described on the Websites is prohibited by law in some jurisdictions. For this reason, persons in countries in which the publication as well as the offering and selling of products and services described on the Websites are not permitted by law, must not enter the Websites and/or acquire the products displayed on the Websites.

Neither Erste Group nor any third party shall offer access to the Websites or offer the products to especially, but not limited to citizen/residents of the United States and “U.S. person” (as defined in Regulation S under the US Securities Act 1933 as amended). For this reason, the distribution or redistribution of the information, materials and products into United States or into any other jurisdiction where it is not permitted under the applicable law, as well as to the citizens/residents of these countries shall be prohibited. The securities displayed on the Websites have not been and will not be registered under the US Securities Act of 1933 and trading in the securities has not been approved for purposes of the US Commodities Exchange Act of 1936. For this reason the securities may, inter alia, not be offered, sold or delivered within the United States or, for the account and benefit of U.S. persons.

The Interested Party is solely responsible to examine, whether he may enter the Websites under the law applicable to it. Erste Group shall not be responsible for the distribution of content of any of the Websites to individuals or entities which provide false information about their right to enter the Websites. For this reason Erste Group shall not be liable for any legal claims or damages which may result from the unauthorized entering or reading of the Websites.

By agreeing to this hereto, the Interested Party confirms that
(i) It has read, understood and accepted this Information and the Disclaimer;
(ii) It informed itself about any possible legal restriction and warrants that it is not restricted or prohibited to enter the Websites according to any law applicable; and
(iii) It does not make available the contents of the Websites to any person who is not qualified by law to enter the Websites.